Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country

Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country

Abstract Introduction Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non‐small‐cell lung cancer (NSCLC) and programmed death ligand‐1 (PD‐L1) expression is a recognized biomarker to determine response to therapy. We retrospectively analyzed NSCLC patients in the M...

Full description

Bibliographic Details
Main Authors: Soon Hin How, Lye Mun Tho, Chong Kin Liam, Harissa H. Hasbullah, Gwo Fuang Ho, Ibtisam Muhammad Nor, Mau Ern Poh, Kean Fatt Ho, Muthukkumaran Thiagarajan, Azlina Samsudin, Azza Omar, Choo Khoon Ong, Yong Kek Pang, Sing Yang Soon
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Thoracic Cancer
Subjects:
PDL‐1
immunotherapy
lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14442

Internet

https://doi.org/10.1111/1759-7714.14442

Similar Items